

Adult Thoracic Transplant Recipient Follow-Up Worksheet

FORM APPROVED: O.M.B. NO. 0915-0157 Expiration Date: 10/31/2010

Note: These worksheets are provided to function as a guide to what data will be required in the online TIEDI[®] application. Currently in the worksheet, a red asterisk is displayed by fields that are required, independent of what other data may be provided. Based on data provided through the online TIEDI[®] application, additional fields that are dependent on responses provided in these required fields may become required as well. However, since those fields are not required in every case, they are not marked with a red asterisk.

Recipient Information	
Name:	DOB:
SSN:	Gender:
HIC:	Tx Date:
Previous Follow-Up:	Previous Px Stat Date:
rollow op.	otal bate.
Transplant Discharge Date:	
State of Permanent Residence:*	
Zip Code:★	-
B. H. I. C	
Provider Information	
Recipient Center:	
Followup Center:	
Physician Name: *	
NPI#:★	
	C Transplant Center
Follow-up Care Provided By:*	Non Transplant Center Specialty Physician
	Primary Care Physician
	C Other Specify
Specify:	
ореспу.	
Donor Information	
UNOS Donor ID #:	
Donor Type:	


Patient Status	
Date: Last Seen, Retransplanted or Death *	
	LIVING
Patient Status:*	© DEAD
	© RETRANSPLANTED
Primary Cause of Death:	
Specify:	
Contributory Cause of Death:	
Specify:	
Contributory Cause of Death:	
Specify:	
Hospitalizations:	
Has the patient been hospitalized since the last patient status date: ★	C YES ONO UNK
Number of Hospitalizations:	ST=
Hospitalized for Rejection:	C YES C NO C UNK
Hospitalized for Infection:	C YES NO UNK
Noncompliance:	
Was there evidence of noncompliance with immunosuppression medication during this follow-up period that compromised the patient's recovery:	C YES NO UNK
Functional Status: *	

	I				
	No Limitations				
	C Limited Mobility				
Physical Capacity:	Wheelchair bound or more limited				
	Not Applicable (< 1 year old or hospitalized)				
	C Unknown				
Working for income: ≭	C YES O NO UNK				
If No, Not Working Due To:					
	Working Part Time due to Demands of Treatment				
	Working Part Time due to Disability				
	Working Part Time due to Insurance Conflict				
If Yes:	Working Part Time due to Inability to Find Full Time Work				
	Working Part Time due to Patient Choice				
	Working Part Time Reason Unknown				
	Working, Part Time vs. Full Time Unknown				
	Within One Grade Level of Peers				
	Delayed Grade Level				
Academic Progress:	Special Education				
	Not Applicable < 5 years old/ High School graduate or GED				
	Status Unknown				
	Full academic load				
	Reduced academic load				

Academic Activity Level:	 Unable to participate in academics due to disease or condition Not Applicable < 5 years old/ High School graduate or GED Status Unknown 		
Primary Insurance at Follow-up:	k		
Specify			
Clinical Information			
Height:	ft. in. cm ST=		
Weight:	lbs. kg ST=		
BMI:	kg/m^2		
Graft Status: * Functioning Failed If death is indicated for the recipient, and the death was a result of some other factor unrelated to graft failure, select Functioning.			
Date of Graft Failure: Primary Cause of Graft Failure Other, Specify:	 Primary Non-Function Acute Rejection Chronic Rejection/Atherosclerosis Other, Specify 		
Graft Function: Lung:			
FeV1:*	% ST=		
O2 Requirement at Rest: *	L/min ST=		
	O NO BOS		

	○ Yes, Grade OP
	C Yes, Grade 1
Bronchiolitis Obliterans	C Yes, Grade 2
Syndrome: *	Yes, Grade 3
	Yes, Grade UNK
	Unknown
Bronchial Stricture (Since last follow-up): *	C YES O NO C UNK
If yes, Stent:	C YES C NO C
Post Transplant Events:	
Drug Treated Hypertension:	C YES C NO C UNK
Bone Disease (Symptomatic):	C YES ONO UNK
Chronic Liver Disease:	C YES ONO UNK
Cataracts:	C YES O NO O UNK
Diabetes onset during the follow-up period: *	C YES O NO C UNK
Diabetes: If Yes, Insulin Dependent:	C YES ONO UNK
Renal Dysfunction: *	C YES ONO UNK
If Yes, Creatinine > 2.5 mg/dl:	C YES C NO C UNK
Chronic Dialysis:	C YES ONO UNK
Renal Tx since Thoracic Tx:	C YES ONO UNK
Stroke:	C YES ONO UNK

Drug Treated Hyperlipidemia:	C YES C NO C UNK		
Did patient have any acute rejection episodes during the follow-up period: *	 Yes, at least one episode treated with anti-rejection agent Yes, none treated with additional anti-rejection agent No Unknown 		
Was biopsy done to confirm acute rejection:	 Biopsy not done Yes, rejection confirmed Yes, rejection not confirmed Unknown 		
Post Transplant Malignancy:*	C YES C NO C UNK		
Donor Related:	C YES C NO C UNK		
Recurrence of Pre-Tx Tumor:	C YES C NO C UNK		
De Novo Solid Tumor:	C YES C NO C UNK		
De Novo Lymphoproliferative disease and Lymphoma:	C YES O NO C UNK		



	Acyclovir (Zovirax)		
	Cytogam (CMV)		
	Gamimune		
	Gammagard		
	Ganciclovir (Cytovene)		
If Yes, check all that apply:	☐ Valgancyclovir (Valcyte)		
	HBIG (Hepatitis B Immune Globulin)		
	Flu Vaccine (Influenza Virus)		
	Lamivudine (Epivir) (for treatment of Hepatitis B)		
	☐ Valacyclovir (Valtrex)		
	Other, Specify		
Specify: *			
Specify:			
Other therapies:	C YES NO		
•	_		
	Photopheresis		
If Yes, check all that apply:	Plasmapheresis		
	☐ Total Lymphoid Irradiation (TLI)		
Immunosuppressive Information			
Previous Validated Maintenance Follow- Up Medications:			
Previous Validated Maintenance Follow- Up Medications:			
	Yes, same as validated TRR form		
Were any medications given during the			

	Yes, but different than previous validated reportNone given
Did the physician discontinue all maintenance immunosuppressive medications:	C YES NO
Did the patient participate in any clinical research protocol for immunosuppressive medications: Specify: **	C YES C NO

Immunosuppressive Medications

View Immunosuppressive Medications

Definitions Of Immunosuppressive Follow-Up Medications

For each of the immunosuppressant medications listed, check **Previous Maintenance (Prev Maint)**, **Current Maintenance (Curr Maint)** or **Anti-rejection (AR)** to indicate all medications that were prescribed for the recipient during this follow-up period, and for what reason. If a medication was not given, leave the associated box(es) blank.

Previous Maintenance (Prev Maint) includes all immunosuppressive medications given during the report period, which covers the period from the last clinic visit to the current clinic visit, for varying periods of time which may be either long-term or intermediate term with a tapering of the dosage until the drug is either eliminated or replaced by another long-term maintenance drug (example: Prednisone, Cyclosporine, Tacrolimus, Mycophenolate Mofetil, Azathioprine, or Rapamycin). This does not include any immunosuppressive medications given to treat rejection episodes.

Current Maintenance (Curr Maint) includes all immunosuppressive medications given at the current clinic visit to begin in the next report for varying periods of time which may be either long-term or intermediate term with a tapering of the dosage until the drug is either eliminated or replaced by another long-term maintenance drug (example: Prednisone, Cyclosporine, Tacrolimus, Mycophenolate Mofetil, Azathioprine, or Rapamycin). This does not include any immunosuppressive medications given to treat rejection episodes.

Anti-rejection (AR) immunosuppression includes all immunosuppressive medications given for the purpose of treating an acute rejection episode since the last clinic visit (example: Methylprednisolone, Atgam, OKT3, or Thymoglobulin). When switching maintenance drugs (example: from Tacrolimus to Cyclosporine; or from Mycophenolate Mofetil to Azathioprine) because of rejection, the drugs should not be listed under AR immunosuppression, but should be listed under maintenance immunosuppression.

Note: The Anti-rejection field refers to any anti-rejection medications since the last clinic visit, not just at the time of the current clinic visit.

If an immunosuppressive medication other than those listed is being administered (e.g., new monoclonal antibodies), select Previous Maint, or Current Maint, or AR next to Other Immunosuppressive Medication field, and enter the full name of the medication in the space provided. **Do not list non-immunosuppressive medications.**

		Maint	Maint	
Steroids (Prednisone, Methylprednisolone, Solumedrol, Medrol, Decadron)				
Atgam (ATG)				
OKT3 (Orthoclone, Muromonab)				
Thymoglobulin				
Simulect - Basiliximab				
Zenapax - Daclizumab				
Azathioprine (AZA, Imuran)				
EON (Generic Cyclosporine)				
Gengraf (Abbott Cyclosporine)				
Other generic Cyclosporine, specify brand:				
Neoral (CyA-NOF)				
Sandimmune (Cyclosporine A)				
CellCept (Mycophenolate Mofetil; MMF)				
Generic MMF (Generic CellCept)				
Prograf (Tacrolimus, FK506)				
Generic Tacrolimus (Generic Prograf)				
Modified Release Tacrolimus FK506E (MR4)				
Sirolimus (RAPA, Rapamycin, Rapamune)				
Myfortic (Mycophenolate Sodium)				
Other Immunosuppressive Medications				_
	Prev Maint	Curr Maint	AR	
Campath - Alemtuzumab (anti-CD52)	Maint	IVIAITIL		
Cyclophosphamide (Cytoxan)				
Leflunomide (LFL, Arava)				
Methotrexate (Folex, PFS, Mexate-AQ, Rheumatrex)				

Other Immunosuppressive Medication, Specify			
Rituximab			
Investigational Immunosuppressive Medications			
	Prev Maint	Curr Maint	AR
Everolimus (RAD, Certican)			
Other Immunosuppressive Medication, Specify			
UNOS View Only			
Comments:			

Copyright @ 2010 United Network for Organ Sharing. All rights reserved.

Public Burden/Privacy Act Statements